GLP-1 receptor agonists, beyond their established role in diabetes and weight management, demonstrate potential anticancer properties that could enhance total neoadjuvant therapy for locally advanced rectal cancer. These medications appear to work through multiple mechanisms: reducing visceral fat, improving insulin resistance, and decreasing systemic inflammation—all factors that can influence tumor biology and treatment response. The metabolic optimization achieved by GLP-1 receptor agonists may create a more favorable environment for chemotherapy effectiveness while potentially improving surgical outcomes. This represents an intriguing convergence of metabolic medicine and oncology, suggesting that addressing metabolic dysfunction could be a legitimate cancer treatment strategy rather than merely supportive care. However, this remains largely theoretical territory. The evidence is primarily observational and preclinical, lacking the robust clinical trials needed to establish efficacy and safety in cancer patients. The concept is particularly compelling for metabolically compromised patients, who often face worse cancer outcomes, but definitive proof requires controlled studies examining whether GLP-1-induced metabolic improvements translate to measurably better oncological results.